논문KCI 등재
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Type 2 diabetes as a key metabolic risk factor for ad verse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”Heejoon Jang, Won Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial 2 on “Impacts of metabol ic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”Mindie H. Nguyen, Rui Huang대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial 1 on “Impacts of metabol ic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”Mindie H. Nguyen, Rui Huang대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”Jia-Horng Kao, Shang-Chin Huang대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Metabolic dysfunction in patients following DAAinduced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”Chen-Hua Liu, Yu-Ping Chang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on “Switching to besi fovir in patients with chronic hepatitis B receiving te nofovir disoproxil fumarate: A randomized trial”Wai-Kay Seto대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12